What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even ...

Drawing on more than a decade of Medicare data, Rutgers Health researchers found disparities in opioid prescribing and use ...

A federal grant for HIV research is part of $15.7 million the National Institutes for Health awarded to the Wertheim UF Scripps Institute in Jupiter.

Lamivudine/dolutegravir is effective as first-line therapy for HIV infection, with low rates of treatment failure.

Patients who achieved HIV virologic suppression tended to be older and were more likely to report continued engagement in HIV care than those with persistent viremia.

An HIV prevention drug will be made available at a new, low cost in 120 low- and middle-income countries starting in 2027, according to an announcement yesterday. The move is being called a “once-in-a ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic ...